Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager by Sostoa, Jana de et al.
RESEARCH ARTICLE Open Access
Targeting the tumor stroma with an
oncolytic adenovirus secreting a fibroblast
activation protein-targeted bispecific T-cell
engager
Jana de Sostoa1, Carlos Alberto Fajardo1, Rafael Moreno1, Maria D. Ramos1, Martí Farrera-Sal1,2 and
Ramon Alemany1*
Abstract
Background: Oncolytic virus (OV)-based therapies have an emerging role in the treatment of solid tumors,
involving both direct cell lysis and immunogenic cell death. Nonetheless, tumor-associated stroma limits the
efficacy of oncolytic viruses by forming a barrier that blocks efficient viral penetration and spread. The stroma also
plays a critical role in progression, immunosuppression and invasiveness of cancer. Fibroblast activation protein-α
(FAP) is highly overexpressed in cancer-associated fibroblasts (CAFs), the main cellular component of tumor stroma,
and in this study we assessed whether arming oncolytic adenovirus (OAd) with a FAP-targeting Bispecific T-cell
Engager (FBiTE) could retarget infiltrated lymphocytes towards CAFs, enhancing viral spread and T cell-mediated
cytotoxicity against the tumor stroma to improve therapeutic activity.
Methods: The bispecific T-cell Engager against FAP was constructed using an anti-human CD3 single-chain variable
fragment (scFv) linked to an anti-murine and human FAP scFv. This FBiTE was inserted in the oncolytic
adenovirus ICOVIR15K under the control of the major late promoter, generating the ICO15K-FBiTE. ICO15K-
FBiTE replication and potency were assessed in HT1080 and A549 tumor cell lines. The expression of the
FBiTE and the activation and proliferation of T cells that induced along with the T cell-mediated cytotoxicity
of CAFs were evaluated by flow cytometry in vitro. In vivo, T-cell biodistribution and antitumor efficacy studies
were conducted in NOD/scid/IL2rg−/− (NSG) mice.
Results: FBiTE expression did not decrease the infectivity and replication potency of the armed virus. FBiTE-
mediated binding of CD3+ effector T cells and FAP+ target cells led to T-cell activation, proliferation, and
cytotoxicity of FAP-positive cells in vitro. In vivo, FBiTE expression increased intratumoral accumulation of T cells and
decreased the level of FAP, a marker of CAFs, in tumors. The antitumor activity of the FBiTE-armed adenovirus was
superior to the parental virus.
Conclusions: Combination of viral oncolysis of cancer cells and FBiTE-mediated cytotoxicity of FAP-expressing CAFs
might be an effective strategy to overcome a key limitation of oncolytic virotherapy, encouraging its further clinical
development.
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Background
Oncolytic viruses (OVs) are emerging as promising
anti-tumor agents in cancer treatment, offering an
attractive combination of tumor-specific cell lysis and
intratumoral immune stimulation. Engineered OVs have
been tested in several Phase I-III clinical trials, and
Talimogene laherparepvec (Imlygic®), an Herpes Simplex
Virus (HSV) expressing the granulocyte macrophage
colony stimulating factor (GM-CSF), has been recently
approved by FDA and EMA for the treatment of melan-
oma. Despite their potential, OVs have several limita-
tions that should be tackle to improve their efficacy.
One of the major obstacles to successful oncolytic
therapy is the presence of stroma in tumors, formed by
different types of cells and extracellular matrix (ECM)
compounds. Stroma not only creates physical barriers
that limit oncolytic adenovirus (OAd) spread across the
tumor, but also induces tumor progression by enhancing
the survival, proliferation, stemness, metastasis, and an
immunosuppressive microenvironment that limits tumor
immunity, ultimately promoting cancer progression, but
also enhancing resistance to therapy [1]. One attractive
stromal target is the fibroblast activation protein-α
(FAP), a transmembrane serine protease that is highly
expressed on the cell surface of cancer-associated fibro-
blasts (CAFs), which represent the key component in
the tumor microenvironment of many cancers [2].
Accordingly, several immunotherapeutic strategies to
deplete FAP-expressing stromal cells have already been
explored [3–11].
Another important hurdle for the efficacy of OVs is
the host immune response to the OV. Antiviral immune
responses can intrinsically limit OV infection, spread,
and overall therapeutic efficacy. However, there is
increasing evidence that virus-mediated destruction or
damage of tumors can lead to an antitumor immune
response [12]. Thus, novel strategies to minimize the
antiviral immune response for successful virus growth
and retreatment, but to stimulate antitumor responses,
would provide an opportunity to tilt this balance in favor
of the therapeutic benefit.
Based on the pro-tumorigenic functions of tumor
stroma and the strong antiviral immune responses that
limit OV therapy, the destruction of CAFs by arming
OVs with FAP-targeting Bispecific T-cell Engagers
(BiTEs) may mitigate the key limitations of OVs [3].
BiTE antibody constructs comprise tandemly-arranged
single-chain variable fragments (scFvs). One scFv binds
the TCR CD3ε subunit and the other binds a
tumor-associated surface antigen (TAA). The simultan-
eous binding of the BiTE to the CD3 on T cells and to
the TAA on target cells leads to the formation of the im-
munological synapse due to the close proximity of both
membranes, leading to polyclonal T-cell activation,
expansion and lysis of the protein-expressing target cells.
Blinatumomab (Blincyto®), a first-in-class BiTE, has
shown promise results for treating relapsed/refractory pre-
cursor B cell acute lymphoid leukemia (ALL) [13]. We
have previously generated an anti-EGFR BiTE-armed
OAd, which showed to improve T cell-mediated killing of
cancer cells both in vitro and in vivo [14].
Here we report the development of the OAd
ICO15K-FBiTE encoding FAP-targeting BiTE to retarget
infiltrated lymphocytes against FAP-expressing CAFs.
We show the ability of ICO15K-FBiTE to induce strong
and specific T-cell activation and proliferation upon in-
fection, leading to T cell-mediated cytotoxicity of CAFs




Human cell lines A549 (lung adenocarcinoma), HEK293
(embryonic kidney), HT1080 (fibrosarcoma), A431
(vulval epidermoid carcinoma), Jurkat (T-cell leukemia)
and HPAC (pancreatic adenocarcinoma) were obtained
from the American Type Culture Collection (ATCC).
Human CAFs pf179 (named as hCAFs) were kindly pro-
vided by Varda Rotter (Weizmann Insitute of Science,
Israel). 293, 293mFAP and 293hFAP cell lines were ob-
tained from Dr. Eric Tran (National Institutes of Health,
Bethesda, MD). Murine CAFs were isolated from HPAC
tumors as described [15]. To generate FAP-expressing
cell lines, HT1080 and A431 cells were transduced with
a lentivirus encoding either the mouse or the human
FAP cDNA (Dharmacon). FAP-expressing cells were
sorted and expanded. HT1080 cells stably expressing
mouse FAP or human FAP are designated as HT-mFAP
and HT-hFAP, respectively. A431 cells are designated as
A431-mFAP and A431-hFAP. All tumor cell lines were
maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with inactivated 10% fetal bo-
vine serum (FBS, Invitrogen Carlsbad) and 1X Penicillin/
Streptomycin (PS, Gibco) at 37 °C, 5% CO2 incubator,
except for Jurkat cells which were maintained in
RPMI-1640 medium. All cell lines were routinely tested
for mycoplasma.
Preparation of peripheral blood mononuclear cells and
T cell isolation
All experiments were approved by the ethics committees
of the University Hospital of Bellvitge and the Blood and
Tissue Bank (BST) from Catalonia. Blood samples were
obtained from the BST from Catalonia. Peripheral blood
mononuclear cells (PBMCs) were isolated by ficoll
density gradient centrifugation. PBMCs were treated
with ACK lysis buffer (Lonza) and resuspended in
RPMI-1640 medium supplemented with 10% FBS. T
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cells were isolated using the Rosette-Sep Human T Cell
Enrichment Cocktail (STEMCELL Technologies). For
stimulation, T cells were cultured with CD3/CD28-acti-
vating Dynabeads (Thermo Fisher Scientific) at 1:3
bead-to-cell ratio. For bioimaging studies, T cells were
transduced with a lentivirus expressing GFP and the
click beetle green luciferase (CBG) (multiplicity of infec-
tion (MOI) of 7) 24 h hours after activation. Cells were
counted and fed every day until day 10, time point at
which they were either used for functional assays or
cryopreserved.
FBiTE and construction of recombinant adenoviruses
FBiTE was generated by joining the scFvs anti-FAP and
anti-CD3ɛ with a GGGGS flexible linker. The anti-CD3
scFv sequence of the Blinatumomab BiTE was obtained
from patent application WO2004106381. The anti-FAP
sequence (FAP5) was derived from patent application
US 2009/0304718 A1 and showed affinities of 5 nM for
human FAP and 0.6 nM for mouse FAP [10]. The FAP5
and anti-CD3 variable regions were connected by a
(G4S1)3 and a (G2S1)4GG linker, respectively. The FBiTE
was arranged VL(FAP5)-VH(FAP5)-VH(CD3)-VL(CD3)
and contained an N-terminal signal peptide derived from
the mouse immunoglobulin light chain for mammalian se-
cretion, and a FLAG tag at the C-terminal for detection.
The FBiTE construct was optimized for human codon
usage and synthesized by Baseclear (pUC57-FBiTE
plasmid, Baseclear). The genome of ICO15K-FBiTE was
obtained by recombineering in bacteria as described [16].
HEK293 cells were transfected with the resulting plasmid
pAdZ-ICO15K-FBiTE with calcium phosphate standard
protocol. ICO15K-FBiTE was plaque-purified and further
amplified in A549 cells. Viruses were double purified by
cesium chloride gradient centrifugation and tittered using
anti-hexon staining.
Production of FBiTE-containing supernatants
A549 cells (1 × 107) were infected at MOI of 20 with
ICO15K or ICO15K-FBiTE. 72 h post-infection, superna-
tants were collected and centrifuged 5min at 1200 g to
eliminate detached cells. Supernatants from uninfected
cells were used as a mock control. For binding assays,
supernatants were concentrated (approximately 20x)
with Amicon Ultra-15 filter units with a molecular
weight cutoff of 30 kDa (Merck Millipore). Aliquots of
the supernatant were stored at − 20 °C for future
analysis.
Antibodies and flow cytometry
Flow cytometry analysis was performed on a Gallios
cytometer (Beckman Coulter) and data was processed
with FlowJo v7.6.5 (Tree Star). Murine FAP expression
was detected with the mouse 73.3 antibody kindly
provided by Dr. Ellen Puré (Abramson Family Cancer
Research Institute, Philadelphia, Pennsylvania) and hu-
man FAP expression was detected with F19 hybridoma
(ATCC). For analysis of T cell populations, antibodies
CD3 (clone OKT3), CD4 (OKT4) and CD8 (SK1) (Biole-
gend) were used. The FITC-conjugated anti-FLAG M2
monoclonal antibody (Sigma Aldrich) was used to detect
the BiTE in binding assays. In each case, appropriated
isotype controls were used (Santa Cruz Biotechnology).
Binding assays
Binding assays were performed with HT1080 cells
transfected with either human or murine FAP antigen or
CD3+ Jurkat cells. HT1080 (2 × 105) or Jurkat (1 × 105)
cells were incubated on ice for one hour with the con-
centrated or unconcentrated supernatants. BiTE binding
was determined by flow cytometry using anti-FLAG
M2-FITC antibody (Sigma Aldrich).
In vitro co-culture experiments
Tumor cells (3 × 105) and PBMCs or T cells (effector--
to-target ratio of 5) were seeded in 96-well plates in
100 μl of medium. For cytokine production assays,
100 μl of the supernatants were added to the wells. Su-
pernatants were collected after 24 h of incubation and
assessed for human IFN-ɣ, TNF-α, and IL-2 using the
ELISA MAX Deluxe set (Biolegend), following the man-
ufacturer’s protocol. For PBMCs or T-cell proliferation
assays, PBMCs or T cells were labeled with 1 μmol/L
Carboxyfluorescein succinimidyl ester (CFSE) (Sigma
Aldrich) and co-cultured as described above for 6 days
(PBMCs) or 3 days (T cells). Cells were then stained for
cell viability with LIVE/DEAD (Thermo Fisher Scien-
tific) and for CD4 and CD8 (Biolegend). Flow cytometry
analysis was performed by acquiring a total of 20,000
events.
Cytotoxicity assays
Viral cytotoxicity assays were performed as previously
described [17]. IC50 was calculated with GraphPad Prsim
v6.02 (GraphPad Software Inc.) by a dose-response non-
linear regression with a variable slope.
To assess FBiTE-mediated cytotoxicity, CFSE-labeled
target cells (HT1080, mCAFs (3 × 104) or hCAFs (1 ×
104)) were cultured with 1,5 × 105 T cells (E:T = 5) in
96-well plates or 48-well plates, respectively. 100 μl of
mock, ICO15K or ICO15K-FBiTE supernatants were
added. After 24 h of incubation, cocultures were tryp-
sinized and stained with LIVE/DEAD® (Thermo Fisher
Scientific). Cells were analyzed by flow cytometry and
the percentage of CFSE+/LIVE and DEAD+ was
determined.
For bystander killing assays, FAP-negative cells
(HT1080 and A431) were cultured in the presence of T
Sostoa et al. Journal for ImmunoTherapy of Cancer            (2019) 7:19 Page 3 of 15
cells and its derivative mFAP or hFAP cells (E:T = 5) and
100 μl of supernatants were added. After 24 h, the cyto-
toxicity of the FAP-negative cells and mFAP or hFAP
cells were determined by flow cytometry. mFAP- and
hFAP-expressing cells were identified as a CFSE-
hCD45- double negative cells. The percentage of CFSE+/
LIVE and DEAD+ cells and CFSE-/hCD45−/LIVE and
DEAD+ cells was determined.
FBiTE-mediated cytotoxicity of FAP-positive non-in-
fected cells was assessed infecting A549 cells in suspen-
sion with ICO15K or ICO15K-FBiTE (MOI = 20). After
4 h, infected cells were washed thrice with PBS. 3 × 104
A549-infected cells were mixed with 3 × 104
CFSE-labeled target cells (1:1), T cells (E:T = 5) and
supernatants (100 μl). After three days of incubation, co-
cultures were stained and analyzed as described above.
Xenograft mouse models
All animal experiments were approved by the Ethics Com-
mittee for Animal Experimentation from Biomedical Re-
search Institute of Bellvitge (IDIBELL). A549 (4 × 106) or
HPAC (2 × 106) cells were subcutaneously injected into
each flank of female, 8-week-old, NOD/scid/IL2rg−/−
(NSG) mice (bred in house). Once tumors reached a
median volume of 120mm3, mice were randomized prior
to treatment.
To evaluate T-cell trafficking to the tumor, mice bearing
A549 tumors were treated intratumorally with PBS, ICO15K,
or ICO15K-FBiTE (1 × 109 vp/tumor). Four days later, 1 ×
107 preactivated GFP- and CBG-luciferase-expressing T cells
(LUC-T-cells) were intravenously injected to treated mice.
Mice were given an intraperitoneal injection of 15mg/mL
D-luciferin potassium salt solution (Byosinth AG) and
imaged daily for 7 days using IVIS Lumina XRMS Imaging
System (PerkinElmer).
For antitumor efficacy studies, mice were treated
intratumorally with PBS or the indicated viruses (1 × 109
vp/tumor). Tumors were measured twice or thrice a week
with a digital caliper and tumor volume was determined
with the eq. V (mm3) = π/6 ×W2 × L, where W and L are
the width and the length of the tumor, respectively.
Immunohistochemistry
To detect FAP and E1A-Adenovirus expression in tu-
mors, immunohistochemistry (IHC) was performed
using OCT-embedded sections (5 μm thick) of freshly
frozen tumor tissues. Sections were fixed with 2% of
PFA at room temperature and endogenous peroxidases
were blocked by incubation in 3% H2O2. Next, sections
were blocked for 1 h with 10% of normal goat serum
diluted in 1% BSA, PBS-Tween. For FAP detection,
primary antibody incubation was performed overnight at
4 °C using a biotinylated polyclonal sheep anti-human/
mouse FAP antibody (5 μg/ml) or its isotype sheep IgG
(R&D systems) in 5% of goat serum. For adenovirus de-
tection, the primary antibody used was an anti-Ad2/5
E1A antibody (Santa Cruz Biotechnology) diluted 1/200
in PBS. The next day, sections were incubated with
ABC-HRP kit (Vectastain) for 30 min, followed by 5 min
incubation with DAKO-DAB substrate (EnVision). Slides
were dehydrated using standard protocols and counter-
stained with haematoxylin.
DNA/RNA quantification by qPCR
Frozen tumor samples were disrupted using a mortar
and pestle under liquid nitrogen. RNA and DNA were
isolated from approximately 25 mg of homogenized
tissue with the DNA/RNA/protein kit (IBI Scientific).
RNA samples were treated with the TURBO DNA-free
kit (Thermo Fisher Scientific) to remove traces of gen-
omic DNA. RNA (1 μg) was retrotranscribed with the
High-Capacity cDNA Reverse Transcription kit (Thermo
Fisher Scientific). Real-time analysis was performed in a
LightCycler 480 Instrument II (Roche). To quantify the
viral genomes and FBiTE transcripts in the tumor, 100
ng of DNA and 40 ng of cDNA in the presence of SYBR
Green I Master (Roche) were used, respectively. PCR
conditions were: 95 °C 10 min, 40 cycles of 95 °C 15 s,
60 °C 1 min and 72 °C 7 min. Viral genome primers
were Ad18852: 5’-CTTCGATGATGCCGCAGTG-3′
and Ad19047R: 5’-ATGAACCGCAGCGTCAAACG-3′
and FBiTE primers were qBiTEF: 5’-CGGCGAGAA
AGTGACAATGAC-3′ and qBiTER: 5’-TTGGTGAGG
TGCCACTTTTC-3′. Standard curves for viral ge-
nomes and FBiTE were prepared by serial dilutions of
known copy numbers of adenovirus plasmid and
pUC57-FBiTE, respectively. To assess murine FAP expres-
sion, 25 ng of cDNA were analyzed with the TaqMan
Gene Expression Assay ref. Mm01329177_m1 (Thermo
Fisher Scientific). PCR conditions were: 50 °C 2min, 95 °C
10min, 40 cycles of 95 °C 15 s and 60 °C 1min. A standard
curve was prepared by serial dilutions of known copy
numbers of a murine FAP-expressing plasmid. Human
FAP-expressing plasmid was also included as negative
control. In all cases, non-retrotranscribed RNA samples,
in a quantity equivalent to the amount cDNA loaded in
the PCR, were used for PCR to discard genomic DNA
contamination.
Statistical analysis
Statistical analyses were performed using GraphPad
Prism software v6.02. All results were expressed as
means ±SD or SEM, as indicated. Two-tailed unpaired
Student's t-test was used to evaluate the statistical sig-
nificance between two groups. One-way ANOVA with
Tukey post hoc tests was used for differences between
three or more groups in a single condition or time point.
P < 0.05 was taken as the level of significance.
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Results
Generation and characterization of an oncolytic
adenovirus secreting a FAP-targeting BiTE
We have recently reported the generation of an oncoly-
tic adenovirus armed with a BiTE targeting the EGFR on
tumor cells (ICO15K-cBiTE) [14]. This approach,
however, does not address the presence of a tumor
stroma which can impair virus spread in the tumor. In
order to simultaneously target cancer cells through
virus-mediated oncolysis and to re-direct immune re-
sponses towards tumor stroma fibroblasts, we engi-
neered the genome of the oncolytic adenovirus ICO15K
to express a FAP-targeting BiTE (FBiTE) (named as
ICO15K-FBiTE). The FBiTE molecule was engineered by
joining with flexible linkers (GS linkers) two scFv, one
specific for human CD3ɛ and the other for murine and
human FAP (Fig. 1a). FAP scFv sequence was specifically
chosen to bind both murine and human to be able to
target the murine CAFs infiltrated in xenograft tumors
in the in vivo experiments. We have previously demon-
strated that the insertion of a transgene after the fiber
gene using an adenoviral splicing acceptor favors its
expression in a replication-dependent manner without
interfering with viral oncolysis [14, 18]. Using this strat-
egy, the FBiTE was inserted under the control of the
adenovirus major late promoter (Fig. 1a).
To evaluate whether the FBiTE insertion affected the
viability and the oncolytic properties of the virus, we
first compared the replication kinetics of ICO15K and
ICO15K-FBiTE in A549 cells. We observed a minor,
although not significant, loss in the production yields
from cell extracts and supernatants of ICO15K-FBiTE
compared to the parental virus (Fig. 1b). We next
assessed the killing kinetics of the virus in dose-response
cytotoxicity assays in three cancer cell lines (A549,
HT1080 and hCAF). As shown, the FBiTE-expressing
adenovirus conserved oncolytic properties despite slight
increases in IC50 values compared to the parental virus.
We next determined whether FBiTEs encoded by
ICO15K-FBiTE were properly secreted from cancer
cells upon infection, and whether they could retain
their antigen-binding specificities. To this end, we
performed binding assays with HT1080 cells that had
been genetically modified to express either human or
murine FAP. FBiTE binding was detected by flow
cytometry with a fluorescently-labeled anti-FLAG
a b
c
Fig. 1 In vitro characterization of ICO15K-FBiTE. a Schematic structure representation of ICO15K-FBiTE. VL and VH domains of anti-mhFAP and
CD3Ɛ are connected by glycine and serine flexible linkers, flanked by the light chain immunoglobulin signal peptide (SP) and the FLAG tag (FT).
FBiTE is inserted after the adenovirus fiber gene under the control of the major late promoter (MLP). b Viral production from cell extracts (CE)
and supernatants (SN) of ICO15K-FBiTE. A549 cell line was infected with ICO15K or ICO15K-FBiTE. At indicated time points, cell extracts and
supernatants were harvested and titrated by an anti-hexon staining-based method. C. Comparative cytotoxicity profile of ICO15K-FBiTE. A549,
HT1080 and hCAFs cells were infected with serial dilutions of ICO15K or ICO15K-FBiTE. Cell viability was measured at day 6 post-infection for A549
and HT1080 and at day 7 for hCAFs. Mean values ± SD are plotted in B and C (n = 3). TU, transducing units: number of functional viral particles
capable of transducing a cell
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antibody. FBiTE molecuels were detected in the
ICO15K-FBiTE supernatants, and they bound specifically
to HT-mFAP and HT-hFAP but not to the FAP-negative
HT1080-parental cell line (Fig. 2a upper and middle
panels). Moreover, FBiTE molecules were also able to bind
to CD3-positive Jurkat cells (Fig. 2a lower panels). CD3+
bindings were more pronounced when supernatants were
concentrated (dashed lines) but FAP+ bindings were only
detected when concentrated.
Supernatants from ICO15K-FBiTE-infected cells induce
activation and proliferation of T cells
In order to detect the FBiTE-mediated T-cell effector
functions, we evaluated both cytokine production and
proliferation of T cells after co-culture with 293 cells,
either expressing or not murine or human FAP, in the
presence of supernatants from adenovirus-infected
(ICO15K or ICO15K-FBiTE) or uninfected cells (mock).
After 24 h of incubation, supernatants were collected
a b
c
Fig. 2 FBiTE expressed by ICO15K-FBiTE specifically binds to both target and effector cells and is able to activate T cells. a HT1080 (HT), HT-mFAP,
HT-hFAP and Jurkat cells were incubated with mock, ICO15K, or ICO15K-FBiTE supernatants and FBiTE binding was detected by flow cytometry.
b Average concentration values of IFN-ɣ, TNF-α and IL-2 cytokines were measured by ELISA assay using supernatants from 24 h co-cultures of
HEK293 (293), 293mFAP or 293hFAP cells with T cells (E:T = 5) and indicated supernatants. c T-cell proliferation following co-cultures with target
cells and indicated supernatants (E:T = 5). A representative result of triplicates is shown. ***, ICO15K-FBiTE significant (P < 0.001) versus mock or
ICO15K using one-way ANOVA test with post hoc analysis
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and T-cell activation was assessed by quantifying IFN-ɣ,
TNF-α, and IL-2 by ELISA (Fig. 2b). Significant cytokine
release was observed in co-cultures of T cells and
FAP-expressing cells and in the presence of
ICO15K-FBiTE supernatants. Cytokines levels were
higher in the presence of murine FAP-expressing cells
compared to human FAP-expressing target cells. This in
line with the affinity of the FAP5 monoclonal antibody
from which the scFv in our BiTE is derived, which has
been reported to be 5 nM for human FAP and 0.6 nM
for mouse FAP [10]. Importantly, there was no cytokine
production in the absence of FAP+ targets (293 control
cells) or when using supernatants from a parental virus
or from non-infected cells. These data demonstrate that
FBiTE molecules secreted from infected cells are able to
activate T cells in FAP-expression dependent manner.
To further confirm the FBiTE-mediated induction of
T-cell effector functions, we evaluated T-cell prolifera-
tion after 3 days of co-culture. Both CD4+ and CD8+ T
cells showed proliferation only in the co-cultures
containing FAP-expressing cells and the ICO15K-FBiTE
supernatants (Fig. 2c). After performing the same ana-
lysis with PBMCs instead of isolated T cells, both CD4+
and CD8+ T cells showed strong proliferation always in
the co-cultures of PBMCs with FBiTE-containing
supernatants, even in the absence of FAP-expressing
cells (Additional file 1). These results support previous
research which showed that a population of macro-
phages in PBMCs express FAP [19]. To avoid unspecific
FBiTE activation of T cells in PBMCs, we used isolated
T cells for further experiments.
Combining viral oncolysis with FBiTE-mediated killing
improves therapeutic activity in vitro
Having shown the expression of FBiTE from ICO15K-
FBiTE-infected cells, we next investigated FBiTE-medi-
ated cytotoxicity in vitro. We first evaluated the effect of
co-culturing HT1080 and its derivative FAP-expressing
cell lines with T cells and the indicated supernatants.
Marked cytotoxicity of FAP-positive engineered cell lines
was observed after 24 h of incubation only in the pres-
ence of ICO15K-FBiTE supernatants (Fig. 3a). A recent
study demonstrated that BiTEs can also mediate a by-
stander tumor cell killing of nearby cells lacking the tar-
geted antigen [20]. To evaluate this, we co-cultured
CFSE stained FAP-negative cells (HT or A431) with T
cells and its derivative mFAP or hFAP-positive cells,
and supernatants were added. After 24 h, the cytotox-
icity of the CFSE-FAP-negative cells and the mFAP or
hFAP-expressing cells was determined by flow cytometry.
mFAP and hFAP cells were identified as a CFSE- hCD45-
double negative cells. In both cell lines we observed some
cytotoxicity of FAP-negative cells (from 15 to 20%) only
when co-cultured together with FAP-positive cells and
ICO15K-FBiTE supernatants. This result supports an
existing BiTE-dependent T cell-induced bystander lysis of
FAP-negative cells proximal to FAP-positive cells
(Additional file 2).
We next investigated the potential of combining viral
oncolysis and FBiTE-mediated killing of FAP-positive
non-infected cells. To this end, A549 cells were infected
with ICO15K-FBiTE or parental ICO15K at an MOI 20.
After 4 h of incubation, cells were washed and
co-cultured with HT or HT-FAP-CFSE-stained cells and
T cells. In this setup, A549 cells act as FBiTE producers
whereas HT cells represent the target cells. The expres-
sion of OAd-infected cells specifically increased the
cytotoxicity of FAP-positive target tumor cells (Fig. 3b).
These results demonstrate that expression of FBiTE is
compatible with viral replication and sufficient to
achieve the combined oncolysis and FBiTE T-cell medi-
ated killing of the non-infected targeted cells in vitro.
Although the above-mentioned experiments prove the
FBiTE-mediated killing of FAP-expressing cancer cell
lines, the ultimate goal of the secreted FBiTE is to target
the FAP+ CAFs in the tumor microenvironment. To
demonstrate the therapeutic potential of the FBiTE in
that context, cytotoxicity experiments were performed
by co-culturing murine CAFs (mCAFs) and human
CAFs (hCAFs) with human T cells and the different su-
pernatants. As shown in Fig. 3c, T-cell-mediated killing
of both mCAFs and hCAFs was observed in co-cultures
containing the ICO15K-FBiTE supernatant. These
results not only confirm the cytotoxic potential of the
secreted FBiTE, but also demonstrate that mCAFs can
be targeted and killed by human T cells, a prerequisite
for the use of in vivo xenograft models in which the
stroma is from mouse origin.
ICO15K-FBiTE increases tumor T-cell retention and
accumulation in vivo
In order to evaluate T-cell trafficking to ICO15K-FBi-
TE-treated tumors, a biodistribution imaging study was
performed. Preactivated T cells were transduced with a
lentiviral vector expressing GFP and the Click Beetle
Green (CBG) luciferase. We obtained 64%
GFP-CBG-positive cells (Additional file 3A), of which 64%
were CD4+ and 33% were CD8+ (Additional file 3B). Tu-
mors were injected with PBS, ICO15K, or ICO15K-FBiTE
when reached approximately 120mm3, and four days
post-treatment 1 × 107 LUC-T cells were intravenously
injected to all mice groups. Mice were imaged every day
until sacrificed. ICO15K-FBiTE-treated tumors showed
significant enhanced T-cell retention and accumulation
from the first day post-injection, increasing daily unto
reaching a peak at day 6 (Fig. 4). This result proved the
feasibility of the bystander therapy in an in vivo scenario.
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ICO15K-FBiTE-mediated oncolysis enhances antitumor
efficacy in vivo
We next assessed whether the accumulation of
FAP-targeted-T cells observed in ICO15K-FBiTE-treated
mice could improve the antitumor efficacy in A549
(human lung cancer) and HPAC (human pancreatic)
tumor models. It has previously shown that these tumor
models generate FAP+ stroma once implanted subcuta-
neosly in NSG mice [5, 7]. Tumor-bearing mice were
randomized into treatment groups and treated with a
single intratumoral administration of PBS, ICO15K or
ICO15K-FBiTE (1 × 109 vp/tumor) when the tumor
volume reached a mean of 120mm3. We first evaluated
the antitumor activity of our viruses in both tumor
models in the absence of T cells (Fig. 5a). The treatment
with either the FBiTE-armed or parental viruses induced
a similar significant level of efficacy compared to the
PBS group (Fig. 5a). Then we assessed the antitumor ac-
tivity only in presence of T cells (Fig. 5b-e), therefore it
should not be directly compared to Fig. 5a. Four days
post-virus-treatment, 1 × 107 preactivated T cells were
injected intravenously once (HPAC) or twice (A549) to
all mice-treated groups. Based on our pilot studies which
classified HPAC tumors as fast growing, only a single
dose of T cells was performed. We observed no signifi-
cant weight loss in these experiments (Additional file 4).
In the A549 model, a model that grows much more
slowly than HPAC, there were no differences in tumor
growth among the different groups up to day 15 (Fig. 5b,
Additional file 5a). After this day, the mean tumor
growth among treatment groups were statistically
different. In contrast, in the fast-growing HPAC model,
significant differences started earlier, from day 9 (Fig. 5d,
Additional file 5B) but tumor growth was more difficult
to control. In both tumor models, tumors growth of
tumors treated with the FBiTE-expressing adenovirus
were significantly smaller when compared with the
tumors treated with PBS or with the control virus. This
treament also improved significantly the survival (Fig. 5c
and e), providing evidence for the therapeutic benefit of
arming an oncolytic adenovirus with the FBiTE.
ICO15K-FBiTE improves the antitumor activity by
depletion of FAP
We analysed tumor samples from the efficacy studies
described above to demonstrate that the observed
improved antitumor activity was associated to the elim-
ination of CAFs by T cells retargeted with the FBiTE
expressed from the oncolytic adenovirus. We first quan-
tified the viral genomes and the FBiTE copy numbers by
real-time PCR. As expected, we observed high amounts
of viral genomes only in virus-treated tumors compared
a b
c
Fig. 3 Enhanced ICO15K-FBiTE-mediated cytotoxicity of FAP-positive cells. a FBiTE-mediated cytotoxicity was evaluated by flow cytometry after
24 h incubation of CFSE-stained HT1080 cell lines cultured with T cells and indicated supernatants. b CFSE-stained target cells were co-cultured
with A549-infected cells and T cells (E:T = 5). After four days of incubation, specific cytotoxicity of CFSE-stained cells was determined by flow
cytometry. c Cytotoxicity of CFSE-stained-murine or human CAFs was evaluated. Mean values ± SD are plotted in A, B and C (n = 3).
***, ICO15K-FBiTE significant (P < 0.001) by one-way ANOVA test with post hoc analysis compared to mock and ICO15K
Sostoa et al. Journal for ImmunoTherapy of Cancer            (2019) 7:19 Page 8 of 15
to PBS-treated tumors (Fig. 6a), indicating that both
viruses are able to infect and replicate in both tumor
models. This result is further supported by similar findings
when the presence of virus was evaluated by an anti-E1A
immunohistochemistry (Fig. 6d). As expected, we could
detect FBiTE expression only in ICO15K-FBiTE-treated
tumors (Fig. 6b). These data confirm that viruses are
present in the tumor and that the FBiTE is locally
expressed in vivo upon ICO15K-FBiTE infection.
Having shown the in vivo persistence of both viruses
as well as the FBiTE expression by the modified virus,
we next sought to demonstrate the hypothesis that the
enhanced antitumor effect was associated to depletion of
FAP. FAP expression was first quantified by real-time
PCR. As shown in Fig. 6c, the expression of FAP was re-
duced in both tumor models, in ICO15K-FBiTE-treated
tumors compared with the PBS and the control virus.
Consistent with this mRNA quantification data, the
Fig. 4 Increased T cell accumulation in ICO15K-FBiTE tumors. NSG mice bearing A549 (lung carcinoma) tumors were intratumorally treated with
PBS, ICO15K, or ICO15K-FBiTE (1 × 109 vp/tumor). Four days post-virus treatment, all mice received an intravenous injection of 1 × 107 LUC-T-cells
(64% GFP+). Luciferase activity was analyzed by bioluminescence imaging (IVIS) daily until day 7. Mean values ± SEM with ≥5 animals per group
are shown. ***, ICO15K-FBiTE significant (P < 0.001) by one-way ANOVA test with post hoc analysis compared to PBS and ICO15K groups
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amount of FAP protein detected by staining the A549
tumors was also lower (Fig. 6e). Altogether, these results
indicate that the T cells retargeted by the FBiTE are
responsible for killing the FAP-positive murine CAFs in
the tumor mass.
Discussion
Oncolytic adenoviruses (OAds) represent promising
therapeutic agents that promote antitumor effects
through a dual mechanism: selective tumor cell killing




Fig. 5 Enhanced antitumor efficacy of ICO15K-FBiTE in the presence of T cells. a-e NSG mice bearing subcutaneous A549 (lung carcinoma) or
HPAC (pancreatic adenocarcinoma) tumors were intratumorally treated with PBS, ICO15K, or ICO15K-FBiTE (1 × 109 vp/tumor). a. Antitumor activity
in absence of T cells. Mean percentage of tumor growth value ± SEM with ≥12 tumors per group is plotted. b-e Antitumor efficacy in the
presence of T cells. Four days after virus treatment, animals were treated once (HPAC) or twice (A549) with 1 × 107 preactivated T cells. The mean
tumor growth ± SEM of ≥12 tumors per group is shown. d, e Kaplan-Meier survival curves of the experiments described in b and c. *, significant
(P < 0.05) by one-way ANOVA test with post hoc analysis compared to ICO15K group. #, significant (P < 0.05) by one-way ANOVA test with post
hoc analysis compared to PBS group
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several clinical trials with OAds generated promising
albeit modest results [21]. Novel strategies are therefore
needed to overcome the obstacles that prevent success-
ful application of OAds, such as eliminating the tumor
stroma that prevents efficient virus spread and prevent-
ing the immunodominance of the adenoviral epitopes
that promotes fast virus clearance [22, 23].
In the present work, we aimed at addressing these
limitations by arming an oncolytic adenovirus with an
anti-FAP Bispecific T-cell Engager (FBiTE). In contrast
to other therapies, one of the most important advantages
of using BiTEs is its MHC-I-independent mode of action
[24, 25]. BiTEs force T cells and tumor cells to come in
close contact, forming an immunological synapse that
shows all the hallmarks of a synapse formed by T cell
receptor-MHC class I-peptide induced synapses. There-
fore, encoding a BiTE specific against FAP would ideally
re-direct lymphocytes to become cytotoxic against the
tumor stroma, improving virus spread in the tumor
microenvironment. In this study, we have demonstrated
that once the FBiTE is expressed and secreted from in-
fected cells, it can successfully activate both CD4 and
Fig. 6 Depletion of tumor stroma by ICO15K-FBiTE. A549 and HPAC tumors from the antitumor efficacy studies in presence of T cells were
harvested at endpoint of the experiments. a-c Piece of tumor samples were mechanically homogenized, total DNA and RNA were extracted and
quantification by real-time PCR-based method was performed to evaluate a the virus persistence, b FBiTE expression and c levels of FAP
expression in both tumor models. d, e Immunohistochemical stainings of A549 tumors were also performed to assess d presence of virus by
staining the early viral protein E1a and e FAP expression by an anti-FAP antibody. *, significant (P < 0.05) by two-tailed unpaired Student’s t-test.
***, significant (P < 0.001) by two-tailed unpaired Student’s t-test
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CD8 T cells. This activation leads to T-cell-mediated
cytotoxicity of the FAP-expressing cells in vitro and in
vivo and T-cell-induced bystander cell lysis of
FAP-negative cells. Moreover, we have also demon-
strated that the depletion of FAP-positive stromal cells
from the tumor mass enhances the overall antitumor ef-
ficacy without increasing the toxicity. This data confirms
previous results suggesting that targeting FAP enhances
antitumor efficacy and might be therefore a promising
approach for clinical benefits [3–10].
The use of OVs to achieve the local stimulation of
the immune system against the tumor is a hot re-
search field, leading to strong and durable responses [26].
OVs-infected cells create an inflammatory site with the
consequent release of cytokines that activate the immune
system, reverting the immune-suppressive tumor environ-
ment from a “cold” to a “hot” or lymphocyte-infiltrated
tumor. However, the main side effect of the host immune
system is the efficient clearance of the virus counteracting
the oncolytic effect of the treatment. One of the advan-
tages of arming an oncolytic virus with a BiTE is to
balance the antiviral to antitumor immunity by its ability
to re-direct the infiltrated antiviral lymphocytes to kill
cells that express the protein targeted by the BiTE.
It is worth highlighting that arming oncolytic viruses
with BiTEs represents a combined anti-cancer therapy.
Our results show that simultaneously targeting the can-
cer cells with the oncolytic adenovirus and the tumor
stroma with the FBiTE enhances the overall antitumor
efficacy. Other BiTEs encoded by oncolytic viruses have
already been published. The first one was the Ephrin
A2-BiTE-armed oncolytic vaccinia virus, which induced
PBMCs activation and tumor cell cytotoxicity in vitro
and in vivo [27]. In line with that study, similar results
have been described with different OVs armed with
BiTEs [6, 14, 28]. However, all those studies exploited
BiTEs targeting tumor-specific antigens [6, 14, 27, 28].
Thus, the secreted BiTEs can target both infected and
uninfected cells, thereby reducing the virus-driven BiTE
production and availability in the tumor microenviron-
ment. To overcome this limitation, the FBiTE was de-
signed to be expressed by the infected cancer cells and
to target stromal cells, thereby avoiding the depletion of
BiTE-expressing cancer cells and promoting continous
BiTE production dependent on viral oncolysis. In this
regard, a recent report described the benefits of targeting
the tumor stroma with a FAP-targeting BiTE-armed
vaccinia virus in an immunocompetent mouse model of
cancer [3].
One of the major concerns when targeting
non-specific tumor antigens is the potential toxicity.
Despite the controversies of toxicity effects related with
immune targeting, fatal adverse effects have already been
reported in several studies [29]. In this regard, successful
growth inhibition without signs of toxicity by FAP-tar-
geted CARs T-cells has been reported [4, 5, 8]. In con-
trast, Tran et al reported that FAP-targeting with
FAP5-CAR-transduced T cells led to cachexia and lethal
bone toxicities due to FAP expression by multipotent
bone marrow stem cells (BMSCs) [7]. Other studies have
shown that FAP is expressed by some normal tissues
and macrophages [19, 30, 31]. In agreement with this,
we found activation and proliferation of T cells when
PBMCs were co-cultured with FBiTE-containing super-
natants (Additional file 1). Importantly, ICO15K-FBiTE
treatment did not result in any significant off-target tox-
icity in mice, based on body weight and general animal
behavior (Additional file 4). This discrepancy can be ex-
plained by the mode of action of our OV. FBiTE expres-
sion depends on the replication of the OAd in cancer
cells within the tumor microenvironment, in contrast to
CART cells, which circulate freely through the body.
Thus, the strategy of arming oncolytic viruses with a
FAP-targeting BiTE allows the continuous expression of
BiTE directly in the tumor, preventing the targeting of
healthy cells by the BiTE and in turn avoiding possible
adverse effects. In addition, we showed that a single dose
of oncolytic adenovirus is enough to obtain a continuous
expression of BiTE by infected cells, avoiding the needed
of repeated systemic infusion due to short half-life of
BiTEs in serum [32].
Despite the notable improvement of antitumor efficacy
obtained with ICO15K-FBiTE, no complete responses
were observed. These findings may be somewhat limited
by the lack of adequate tumor models used. Using im-
munocompetent models in order to explore the impact
of infiltrating T cells in the tumor after virus injection
would represent a more realistic scenario. However, the
species-specific nature of the adenovirus infection and
replication restricts the appropriate evaluation in im-
munocompetent mouse models. The limited and transi-
ent presence of adoptively transferred lymphocytes in
our model could explain the decrease but incomplete
elimination of FAP+ cells in treated-tumors. Another
reason that could explain the incomplete tumor
rejection could be related to the insufficient activation of
T cells. A recent report has demonstrated the import-
ance of co-stimulation during BiTE-engagement in order
to obtain improved antitumor efficacy [33]. This study
highlights the need of developing improved BiTE con-
structs in order to avoid T cell exhaustion due to chronic
antigen stimulation. In this line, combining this therapy
with other immuno- or chemotherapies may also repre-
sent significant advantages. For example, we have
recently demonstrated that combining BiTE-armed OV
with CART cells improve CART-cell activation and
proliferation in vitro and in vivo, thereby enhancing
T-cell-mediated cytotoxicity [34]. We and others have
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also shown an increase in the expression of T-cell inhibi-
tory receptors after immune-based therapies, likely limit-
ing the antitumor activity [34, 35]. For example, Ribas et
al reported the strong enhanced immune recognition of
cancer when combined talimogene laherparepvec onco-
lytic virus with an anti-PD1 antibody [26]. These studies
support the rationale to combine our BiTE-expressing
virus with different immune checkpoint inhibitors. On
the other hand, Fang et al reported the benefits of com-
bining FAP-targeted therapies with chemotherapies [11].
Such results suggest that destroying the stroma not only
improves virus spread but also may allow chemotherapy
drugs to better penetrate into tumor. It is therefore likely
that the successful application of FAP-targeted by
BiTE-armed oncolytic adenovirus in cancer patients will
require the development of an optimized therapeutic
approach.
Conclusion
This study establishes ICO15K-FBiTE as an effective
strategy for targeting both cancer cells and FAP-positive
stromal cells, killing through combined viral oncolysis
and intratumoral expression of an anti-FAP BiTE. This
approach offers opportunities for cancer therapy with no
evidence of toxicity and further encourages the transi-
tion into clinical applications. Future studies should be
directed towards optimization of both oncolytic adeno-
virus and BiTE designs and to explore the effectiveness
of FAP-targeting BiTE-armed oncolytic adenovirus in
combination with other therapeutic modalities, such as
chemotherapy or other immunotherapies.
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Additional file 1: FBiTEs molecules expressed from ICO15K-FBiTE-
infected cells induce T-cells proliferation when co-cultured with PBMCs.
293, 293mFAP and 293hFAP were co-cultured with CFSE-labeled PBMCs
and indicated supernatants. Six days after co-culture, the CFSE content in
CD4+ and CD8+ T-cells was determined by flow cytometry. A representative
result of triplicates is shown. (DOCX 13487 kb)
Additional file 2: FBiTE-mediated bystander tumor cell killing. A, B.
CFSE-stained HT cells (A) or A431 cells (B) were culture in the presence of
T cells and its derivative mFAP- or hFAP cells and the indicated superna-
tants (mock, ICO15K or ICO15K-FBiTE) were added. After 24 h, cytotoxicity
of HT cells (A) or A431 cells (B) and its mFAP- or hFAP-derivative cells
were evaluated by flow cytometry. Mean values ± SD are plotted in A, B
(n = 3). ***, significant (P < 0.001) by one-way ANOVA test with post hoc
analysis compared to mock and ICO15K. **, significant (P < 0.01) by one-
way ANOVA test with post hoc analysis compared to mock and ICO15K.
(DOCX 168 kb)
Additional file 3: Characterization of GFP- and CBG Luciferase-
expressing T cells. A. Flow cytometry analysis of GFP expression of preac-
tivated T-cells that had been transduced with a lentiviral vector encoding
GFP and the click beetle green (CBG) luciferase. B. Percentages of CD4
and CD8 LUC-T-cells populations determined by flow cytometry.
(DOCX 231 kb)
Additional file 4: Body weight variation in A549 xenograft antitumoral
efficacy assay. Animal body weight was monitored weekly after
intratumoral injection of PBS, ICO15K or ICO15K-FBiTE (2 × 109 vp). Mean
values ± SEM are plotted (n = 6–7). (DOCX 140 kb)
Additional file 5: Antitumor activity of ICO15K-FBiTE. NSG mice bearing
subcutaneous xenografts of A549 or HPAC tumors were injected
intratumorally with PBS or 2 × 109 viral particles of ICO15K or ICO15K-
FBiTE. The mean tumor volume ± SEM of ≥12 tumors per group is shown.
*, significant (P < 0.05) by one-way ANOVA test with post hoc analysis
compared to ICO15K group. #, significant (P < 0.05) by one-way ANOVA
test with post hoc analysis compared to PBS group. (DOCX 195 kb)
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